XML 30 R24.htm IDEA: XBRL DOCUMENT

Entity Wide Disclosures

12 Months Ended

Dec. 31, 2019

16. ENTITY WIDE DISCLOSURES

Operations By Geographic Location

The Company conducts operations in North America, Europe, Africa, Asia-Pacific and Latin America through wholly-owned subsidiaries and representative sales offices. The Company attributes revenue to geographical locations based upon the location of the contracting entity. For the years ended December 31, 2019 and 2018, total revenue attributable to the U.S. represented approximately 95% and 97%, respectively, of total consolidated total revenue.

The following table summarizes property and equipment, net by geographic region and is further broken down to show countries which account for 10% or more of total as of December 31, if any (in thousands):


	2019		2018
Property and equipment, net:
United States	$	25,603	$	38,609
Europe
Belgium		10,045		6,014
Other		5,728		5,500
Total Europe		15,773		11,514
Asia-Pacific		5,671		1,930
Other		245		202
Total property and equipment, net	$	47,292	$	52,255

Revenue by Category

The following table disaggregates the Company’s revenue by major source (in thousands):

	Years Ended December 31,
	2019		2018
Therapeutic Area
Oncology	$	256,766	$	189,056
Other		222,514		163,983
Metabolic		138,650		124,837
Cardiology		91,258		95,213
AVAI		86,390		77,271
Central Nervous System		65,391		54,229
Total revenue	$	860,969	$	704,589

In the current year and for all periods presented, the revenue associated with medical device projects, previously a separate therapeutic area, has been included in the respective therapeutic area that best aligns with the therapeutic focus of the medical device project and represents how management evaluates disaggregated revenue in its internal reporting.